Sonoma Pharmaceuticals, Inc. - Common Stock (SNOA)
2.8800
-0.2600 (-8.28%)
Sonoma Pharmaceuticals Inc is a biotechnology company focused on the development and commercialization of solutions for dermatology and wound care
The company specializes in creating novel, prescriptive and over-the-counter formulations that utilize its patented technology to produce therapeutic products aimed at treating various skin conditions, infections, and wounds. By leveraging advanced science and research, Sonoma Pharmaceuticals aims to enhance patient outcomes and improve the quality of care in the healthcare sector, prioritizing safety and efficacy in its product offerings.
Sonoma stock is trading higher on Tuesday after the company announced that it secured U.K. regulatory clearance for its key wound care and dermatology products.
As we await the opening of the US market on Tuesday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.
SNOA stock results show that Sonoma Pharmaceuticals missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2025.
